Giuseppe Maiolino1, Giacomo Rossitto1, Luigi Pedon1, Maurizio Cesari1, Anna Chiara Frigo1, Matteo Azzolini1, Mario Plebani1, Gian Paolo Rossi2. 1. From the Department of Medicine-DIMED, Clinica dell'Ipertensione Arteriosa UOSD (G.M., G.R., M.C., M.A., G.P.R.), Department of Cardiac, Thoracic, and Vascular Sciences (A.C.F.), and Department of Medicine-DIMED, Laboratory Medicine (M.P.), University of Padua, Padua, Italy; and Dipartimento Area Medica, Divisione di Cardiologia Ospedale di Cittadella, Cittadella, Italy (L.P.). 2. From the Department of Medicine-DIMED, Clinica dell'Ipertensione Arteriosa UOSD (G.M., G.R., M.C., M.A., G.P.R.), Department of Cardiac, Thoracic, and Vascular Sciences (A.C.F.), and Department of Medicine-DIMED, Laboratory Medicine (M.P.), University of Padua, Padua, Italy; and Dipartimento Area Medica, Divisione di Cardiologia Ospedale di Cittadella, Cittadella, Italy (L.P.). gianpaolo.rossi@unipd.it.
Abstract
OBJECTIVE: Galectin-3 (Gal-3) can affect atherogenesis by multiple mechanisms, but it remains scarcely known whether plasma Gal-3 levels predict cardiovascular events in patients with coronary artery disease. Therefore, we investigated if Gal-3 predicts cardiovascular death in patients with coronary artery disease of the Genetic and ENvironmental factors In Coronary Artery disease study. APPROACH AND RESULTS: In a prospective cohort study, we measured the plasma levels of Gal-3 in 1013 randomly selected patients who underwent coronary angiography and long-term follow-up to assess incident cardiovascular events. The primary end points were (1) cardiovascular death and (2) a composite of cardiovascular death, acute coronary syndrome, and stroke. Secondary end points entailed (1) acute myocardial infarction, (2) stroke, and (3) a composite fatal ischemic event including fatal myocardial infarction and stroke. The effect of Gal-3 on prognosis was assessed using Kaplan-Meier analysis and multivariate Cox's regression. During long-term follow-up (median, 7.2 years), 115 cardiovascular deaths occurred (15.2%), more commonly in the high Gal-3 tertile (25.2%) than in the intermediate and the low tertiles (13.6% versus 7.5%, respectively; P<0.001). The adverse prognostic effect of high Gal-3 was confirmed in subgroup analysis of the patients with angiographically documented coronary artery disease and also of those with a normal left ventricular ejection fraction. At multivariate analysis, Gal-3 was a predictor of cardiovascular mortality (hazard ratio, 1.79; 95% confidence interval, 1.10-2.93; P=0.020) along with age, left ventricular ejection fraction, and coronary atherosclerotic burden. CONCLUSIONS: In high cardiovascular risk patients referred for coronary angiography Gal-3 is a strong independent predictor of cardiovascular death.
OBJECTIVE:Galectin-3 (Gal-3) can affect atherogenesis by multiple mechanisms, but it remains scarcely known whether plasma Gal-3 levels predict cardiovascular events in patients with coronary artery disease. Therefore, we investigated if Gal-3 predicts cardiovascular death in patients with coronary artery disease of the Genetic and ENvironmental factors In Coronary Artery disease study. APPROACH AND RESULTS: In a prospective cohort study, we measured the plasma levels of Gal-3 in 1013 randomly selected patients who underwent coronary angiography and long-term follow-up to assess incident cardiovascular events. The primary end points were (1) cardiovascular death and (2) a composite of cardiovascular death, acute coronary syndrome, and stroke. Secondary end points entailed (1) acute myocardial infarction, (2) stroke, and (3) a composite fatal ischemic event including fatal myocardial infarction and stroke. The effect of Gal-3 on prognosis was assessed using Kaplan-Meier analysis and multivariate Cox's regression. During long-term follow-up (median, 7.2 years), 115 cardiovascular deaths occurred (15.2%), more commonly in the high Gal-3 tertile (25.2%) than in the intermediate and the low tertiles (13.6% versus 7.5%, respectively; P<0.001). The adverse prognostic effect of high Gal-3 was confirmed in subgroup analysis of the patients with angiographically documented coronary artery disease and also of those with a normal left ventricular ejection fraction. At multivariate analysis, Gal-3 was a predictor of cardiovascular mortality (hazard ratio, 1.79; 95% confidence interval, 1.10-2.93; P=0.020) along with age, left ventricular ejection fraction, and coronary atherosclerotic burden. CONCLUSIONS: In high cardiovascular risk patients referred for coronary angiography Gal-3 is a strong independent predictor of cardiovascular death.
Authors: Umesh C Sharma; Wassim Mosleh; Milind R Chaudhari; Rujuta Katkar; Brian Weil; Chris Evelo; Thomas R Cimato; Saraswati Pokharel; W Matthijs Blankesteijn; Gen Suzuki Journal: Heart Lung Circ Date: 2016-12-19 Impact factor: 2.975
Authors: Darlene R King; Damilola C Salako; Samia Kate Arthur-Bentil; Arielle E Rubin; Jay B Italiya; Jenny S Tan; Dimitri G Macris; Hunter K Neely; Jayme M Palka; Justin L Grodin; Kaylee Davis-Bordovsky; Matthew Faubion; Carol S North; E Sherwood Brown Journal: J Affect Disord Date: 2020-12-15 Impact factor: 4.839
Authors: Matthew Nayor; Na Wang; Martin G Larson; Ramachandran S Vasan; Daniel Levy; Jennifer E Ho Journal: J Am Heart Assoc Date: 2015-12-31 Impact factor: 5.501
Authors: Rohit M Oemrawsingh; K Martijn Akkerhuis; Victor A Umans; Bas Kietselaer; Carl Schotborgh; Eelko Ronner; Timo Lenderink; Anho Liem; David Haitsma; Pim van der Harst; Folkert W Asselbergs; Arthur Maas; Anton J Oude Ophuis; Ben Ilmer; Rene Dijkgraaf; Robbert-Jan de Winter; S Hong Kie The; Alexander J Wardeh; Walter Hermans; Etienne Cramer; Ron H van Schaik; Imo E Hoefer; Pieter A Doevendans; Maarten L Simoons; Eric Boersma Journal: BMJ Open Date: 2016-12-23 Impact factor: 2.692